US EditionPublished • loading... • Updated
GLP-1 Weight Loss Drugs Are Getting a Major Upgrade After New FDA Approval
Novo Nordisk’s oral Wegovy pill enables significant weight loss with a 14% average reduction, launching amid pricing deals to improve access for Medicare and cash-paying patients.
- On Monday, the U.S. Food and Drug Administration approved an oral version of Novo Nordisk’s Wegovy pill, which the company plans to launch in early January.
- Facing prior setbacks, Novo Nordisk shifted toward an oral high-dose strategy after multiple Phase 3 OASIS trials supported efficacy and digestive system challenges required larger doses.
- Clinical trials found the pill produced substantial weight loss, with oral Wegovy delivering an average 17% weight loss over 64 weeks and the OASIS‑4 trial showing the 25 milligram dose yielded 14% over 71 weeks, rising to 17% for adherent patients.
- Following the approval, Novo shares closed at $51.61, up 7.42%, with trading volume hitting 283% above its three‑month average, and Novo and Lilly pledged $149 starter‑dose pricing in White House deals.
- With rivals waiting in the wings, Eli Lilly’s orforglipron may be approved within weeks via a FDA ‘‘national priority’’ voucher, while Wall Street analysts project more than $100 billion annual GLP‑1 sales by 2030.
Insights by Ground AI
Podcasts & Opinions
11 Articles
11 Articles
Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill
Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Tuesday’s session at $51.61, up 7.30% after U.S. approval of its once-daily oral Wegovy weight-loss pill. Novo Nordisk IPO'd in 1981 and has grown 32,156% since going public. Trading volume reached 65 million shares, coming in about 283% above its three-month average of 16 million shares.Tuesday’s catalysts centered on the FDA’s approval of Novo Nordisk’s…
·Alexandria, United States
Read Full Article
So far, successful treatments, both the Wegovy, sold by Novo Nordisk, and the Mounjaro, its competitor marketed by Eli Lilly, were only in the form of injectable syringes.
·Paris, France
Read Full Article
Coverage Details
Total News Sources11
Leaning Left3Leaning Right1Center3Last UpdatedBias Distribution43% Left, 43% Center
Bias Distribution
- 43% of the sources lean Left, 43% of the sources are Center
43% Center
L 43%
C 43%
14%
Factuality
To view factuality data please Upgrade to Premium
